Data from the nation’s initial set of patients receiving COVID-19 booster shots found similar rates and types of adverse reactions, such as pain at the injection site, headache or fatigue, according to a Centers for Disease Control and Prevention study released today. Within the study group, made up of 12,591 patients with moderate-to-severe immunocompromising conditions who reported on their conditions via CDC’s v-safe surveillance platform, adverse effects occurred with frequencies comparable to those from initial dosing regimens.

Related News Articles

Headline
Most health insurers must cover the updated COVID-19 vaccines from Pfizer and Moderna without cost sharing effective Sept. 11, when the Food and Drug…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response yesterday awarded $600 million for 12 domestic COVID-19…
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
AHA is providing its latest social media toolkit to help hospitals encourage vaccination against COVID-19. The newest toolkit includes messages and assets…
Headline
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…